向日葵：子公司克拉霉素片及辛伐他汀片拟中选国家集采接续采购

Core Viewpoint - The company announced that its subsidiary, Zhejiang Beid Pharmaceutical Co., Ltd., has proposed to be selected for the national centralized procurement of clarithromycin tablets and simvastatin tablets, with the procurement period extending until December 31, 2028 [1] Group 1 - The total sales revenue for the two products in 2024 is projected to be 38.99 million yuan, which accounts for 11.81% of the company's total revenue [1] - If the purchase and sales agreement is signed, it will expand the sales scale of the company [1]